feed,title,long_url,short_url
Benzinga,Single Dose Of NeuBase's Lead Program Shows Encouraging Preclinical Studies,https://benzinga.com/general/biotech/22/03/26120452/single-dose-of-neubases-lead-program-shows-encouraging-preclinical-studies,https://bit.ly/3i8dsQO
Benzinga,FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition,https://benzinga.com/general/biotech/22/03/26118126/fda-declines-to-approve-astrazenecas-asthma-treatment-for-chronic-nasal-condition,https://bit.ly/35WtPNZ
Benzinga,"Pfizer-BioNTech's COVID-19 Shot Moderately Effective Against Omicron In Kids Aged 5 to 15, CDC Study Shows",https://benzinga.com/general/biotech/22/03/26117020/pfizer-biontechs-covid-19-shot-moderately-effective-against-omicron-in-kids-aged-5-to-15-cdc-stud,https://bit.ly/3Kyo9bI
